Substance / Medication

Carisoprodol

Overview

Active Ingredient
carisoprodol
RxNorm CUI
2101

Indications

Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use see Dosage and Administration (2) Carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [].

Labeler: REMEDYREPACK INC.Updated: 2026-02-11T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Carisoprodol is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers.
Zacny James P, Paice Judith A, Coalson Dennis W · Drug Alcohol Depend · 2012
PMID: 21840651RCTFull text (PMC)
Randomized, double-blind trial of carisoprodol 250 mg compared with placebo and carisoprodol 350 mg for the treatment of low back spasm.
Serfer Gregory T, Wheeler William J, Sacks Harry J · Curr Med Res Opin · 2010
PMID: 19908948RCT
FTIR assay method for UV inactive drug carisoprodol and identification of degradants by RP-HPLC and ESI-MS.
Acharya Pratap Chandra, Vasi Ruqaiya, Suares Divya · J Chromatogr B Analyt Technol Biomed Life Sci · 2016
PMID: 27398631Observational
Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.
Kumar Manoj, González Lorie A, Dillon Glenn H · Neuropharmacology · 2015
PMID: 25896767ObservationalFull text (PMC)
Postmortem carisoprodol and meprobamate concentrations in blood and liver: lack of significant redistribution.
McIntyre Iain M, Sherrard James, Lucas Jonathan · J Anal Toxicol · 2012
PMID: 22417833Observational
Determination of carisoprodol and meprobamate in oral fluid.
Coulter Cynthia, Garnier Margaux, Tuyay James et al. · J Anal Toxicol · 2012
PMID: 22417839Observational
Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.
Zacny James P, Paice Judith A, Coalson Dennis W · Pharmacol Biochem Behav · 2011
PMID: 21884720ObservationalFull text (PMC)
Validation of a new homogeneous immunoassay for the detection of carisoprodol in urine.
Wang Guohong, Huynh Kim, Barhate Rekha et al. · J Anal Toxicol · 2011
PMID: 21396230Observational
Quantitative analysis of carisoprodol and meprobamate in whole blood using benzylcarbamate and deuterated meprobamate as internal standards.
Downey Delisa, Simons Kelsie, Ota Kenji et al. · J Anal Toxicol · 2009
PMID: 19671248Observational
Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm.
Ralph Lee, Look Michele, Wheeler William et al. · Curr Med Res Opin · 2008
PMID: 18194591Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Carisoprodol (substance)
SNOMED CT
387133006
UMLS CUI
C0007248
RxNorm CUI
2101
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.